• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Integra LifeSciences Holdings Corporation

    5/30/25 4:44:55 PM ET
    $IART
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email
    SD 1 iart-formsdconflictmineral.htm SD Document

    United States
    Securities and Exchange Commission
    Washington, D.C. 20549
     
    FORM SD
     
     
    Specialized Disclosure Report
     
     
    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    (Exact name of registrant as specified in its charter)
     
     
     
    Delaware 000-26224 51-0317849
    (State or other jurisdiction
    of incorporation or organization)
     
    Commission
    File Number
     
    (I.R.S. Employer
    Identification No.)
    1100 CAMPUS ROAD
    PRINCETON, NEW JERSEY 08540
    (Address of principal executive offices)
     
    Lesha Shinn
    Vice President, Deputy General Counsel & Secretary 
    (609) 275-0500
    (Name and telephone number, including area code, of the person to contact in connection with this report)
     
     
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
     
    x
    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024
     
     
     






    Section 1 — Conflict Minerals Disclosure
    Item 1.01 Conflict Minerals Disclosure
    This Form SD of Integra LifeSciences Holdings Corporation (the “Company”) has been prepared and filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2024 to December 31, 2024 (the “Reporting Period”).
    A copy of the Company’s conflict minerals report prepared in accordance with the Rule for the Reporting Period is attached as Exhibit 1.01 to this Form SD and is also available at the following internet website https://www.integralife.com/ConflictMineralsPolicy.
    The reference to Integra’s website is provided for convenience only, and its contents are not incorporated by reference into this Form SD and the conflict minerals report nor deemed filed with the U.S. Securities and Exchange Commission.
    Item 1.02 Exhibit
    The Company has filed, as Exhibit 1.01 to this Form SD, the conflict minerals report required by Item 1.01.
    Section 2 — Exhibits
    Item 2.01 Exhibits
    The following exhibit is filed as part of this report:
    Exhibit 1.01 — Conflict Minerals Report






    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     

     
    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    Date: May 30, 2025By:/s/ Lea Knight                                 
    Lea Knight
    Title:
    Executive Vice President and Chief Financial Officer


    Get the next $IART alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IART

    DatePrice TargetRatingAnalyst
    3/31/2025Hold → Buy
    Argus
    12/2/2024$25.00 → $20.00Underweight
    Morgan Stanley
    10/7/2024Sell → Neutral
    BTIG Research
    7/30/2024$22.00Neutral → Sell
    BTIG Research
    7/30/2024$30.00 → $23.00Neutral → Sell
    Citigroup
    5/7/2024Outperform → Perform
    Oppenheimer
    5/7/2024$45.00 → $25.00Overweight → Equal Weight
    Wells Fargo
    4/3/2024$38.00Sell → Neutral
    Citigroup
    More analyst ratings